+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rhabdomyosarcoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4517528
  • Report
  • 99 pages
  • Prescient & Strategic Intelligence Private Limited
1 of 2
RMS Therapeutics Pipeline in 2018

RMS is a rare and malignant type of tumor which can arise from skeletal muscles, tendons, or connective tissues. The pathophysiology of this type of cancer is still unknown, but when it arises from the skeletal muscles, it can spread to any part of the body. RMS majorly arises from skeletal muscles, but the reason behind this remains unknown. RMS is the most common soft tissue tumor that occurs during childhood and accounts for approximately half of all soft tissue sarcomas in this age group.

Insights on Pipeline Segments

According to the research findings, most of the drug candidates for the treatment of RMS are being developed to be administered by the intravenous route. The main advantage associated with the intravenous route is that the drug can easily be entered into the bloodstream, or lymph vessels, resulting in high bioavailability of the drug in the body and quick onset of action of drug.

RMS Therapeutics Pipeline is Witnessing Significant Growth due to Development of Combination Therapies

Several companies are developing combination therapies for the treatment of RMS, as these therapies are cost-effective and improve medication compliance by reducing burden of pills. For instance, (Dasatinib + Ganitumab) is a combination therapy under the Phase II stage of development by Bristol-Myers Squibb Company for the treatment of RMS. The drug candidate is a combination of small molecule (dasatinib) and monoclonal antibody (ganitumab), obtained from synthetic and natural source, respectively. It acts as Bcr-abl tyrosine kinase inhibitor and EphA2 receptor antagonist (dasatinib); and insulin-like growth factor-I receptor antagonist (ganitumab).

Combination therapies help to reduce frequency of dose administration, increase synergistic effect, and increase the potency of drugs for the treatment of RMS, thus driving the growth in pipeline.

Advancement in Technology to Support RMS Therapeutics Pipeline Growth

Most of the companies are developing drug candidates using advanced technologies, and these drug candidates have showed positive efficacy in the clinical stage of development. For instance, Iproteos SL is developing its drug candidate using IPROTech technology platform which involves a combination of in-silico and in-vitro techniques. The technology encompasses state-of-the-art of various scientific fields, such as computational chemistry, modern organic synthesis, peptide chemistry, and experimental validation of potency, absorption, distribution, metabolism, and excretion (ADME) and permeability properties.

IPROTech platform is a versatile technology platform that can be applied to a wide variety of proteins. It is based on the repetition of cycles consisting of in-silico and in-vitro techniques. Some of the advantages of this technology include reduction of time and cost for manufacture of drugs, and the ability to render the drugs to reach intracellular targets.

Some of the key players involved in the development of RMS therapeutics include F. Hoffmann-La Roche Ltd., Epizyme Inc. and Novartis AG.
Note: Product cover images may vary from those shown
2 of 2
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents by industry participant by company type

3. Executive Summary

4. Pipeline Outlook
4.1 Disease Overview
4.2 Sign & Symptoms
4.3 Pathophysiology
4.4 Epidemiology
4.5 Diagnosis
4.6 Prevention and Treatment
4.7 Key Drivers
4.7.1 Combination Therapies for the Treatment of RMS
4.7.2 Driver 2
4.8 Key Barriers
4.8.1 Severe Side Effects Involved in the Treatment of RMS
4.9 RMS Therapeutics Pipeline Analysis
4.9.1 Pipeline Analysis by Phase
4.9.2 Pipeline Analysis by Molecule Type
4.9.3 Pipeline Analysis by Route of Administration
4.9.4 Pipeline Analysis by Company

5. RMS Therapeutics Pipeline Analysis by Phase (2018)
5.1 Phase II
5.1.1 Pazopanib Clinical trials
5.1.2 XX Clinical trials Clinical results
5.1.3 XX Clinical trial
5.2 Phase I/II
5.2.1 Afatinib Clinical trial Clinical result Patents
5.2.2 XX Clinical trials Strategic development Technology
5.2.3 XX Clinical trial
5.2.4 XX Pre-Clinical studies Clinical trials
5.2.5 XX Clinical trials Strategic development Technology
5.2.6 XX Clinical trials
5.2.7 XX Clinical trials Strategic development Technology
5.3 Phase I
5.3.1 XX Clinical studies Clinical results Technology
5.4 Pre-Clinical
5.4.1 BIO11006
5.4.2 XX Technology
5.4.3 XX Technology
5.4.4 XX Pre-Clinical studies Grant
5.5 Discovery
5.5.1 XX Technology
5.5.2 XX Technology
5.6 Unknown Phase
5.6.1 XX Strategic development Technology

6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

7. Competitive Landscape
7.1 Key Player Benchmarking for RMS Therapeutics Pipeline
7.2 SWOT Analysis of RMS Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 Veana Therapeutics Inc.
8.1.1 Business Overview
8.1.2 Product and Service Offerings
8.2 Company 2
8.2.1 Business Overview
8.2.2 Product and Service Offerings
8.3 Company 3
8.3.1 Business Overview
8.3.2 Product and Service Offerings
8.4 Company 4
8.4.1 Business Overview
8.4.2 Product and Service Offerings
8.5 Company 5
8.5.1 Business Overview
8.5.2 Product and Service Offerings
8.6 Company 6
8.6.1 Business Overview
8.6.2 Product and Service Offerings
8.7 Company 7
8.7.1 Business Overview
8.7.2 Product and Service Offerings
8.8 Company 8
8.8.1 Business overview
8.8.2 Product and Service Offerings
8.9 Company 9
8.9.1 Business Overview
8.9.2 Product and Service Offerings
8.1 Company 10
8.10.1 Business Overview
8.10.2 Product and Service Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Table 1 Incidence of Rms by Site On Body
Table 2 Pipeline Analysis of Rms Therapeutics, by Company (2018)
Table 3 Description of Pazopanib
Table 4 Clinical Trials of Pazopanib
Table 5 Description of Xx
Table 6 Clinical Trials of Xx
Table 7 Primary Outcome
Table 8 Secondary Outcome
Table 9 Description of Xx
Table 10 Clinical Trials of Xx
Table 11 Description of Afatinib
Table 12 Clinical Trials of Afatinib
Table 13 Description of Xx
Table 14 Clinical Trials of Xx
Table 15 Description of Xx
Table 16 Clinical Trials of Xx
Table 17 Description of Xx
Table 18 Clinical Trials of Xx
Table 19 Description of Xx
Table 20 Clinical Trials of Xx
Table 21 Description of Xx
Table 22 Clinical Trials of Xx
Table 23 Description of Xx
Table 24 Clinical Trials of Xx
Table 25 Description of Xx
Table 26 Clinical Trials of Xx
Table 27 Description of Bio11006
Table 28 Description of Xx
Table 29 Description of Xx
Table 30 Description of Xx
Table 31 Description of Xx
Table 32 Description of Xx
Table 33 Description of Xx
Table 34 Veana Therapeutics Inc. - At a Glance
Table 35 Company 2 - At a Glance
Table 36 Company 3 - At a Glance
Table 37 Company 4 - At a Glance
Table 38 Company 5 - At a Glance
Table 39 Company 6 - At a Glance
Table 40 Company 7 - At a Glance
Table 41 Company 8 - At a Glance
Table 42 Company 9 - At a Glance
Table 43 Company 10 - At a Glance

List of Figures
Fig 1: Research Methodology
Fig 2: Breakdown of Primary Research Respondents, by Industry Participant
Fig 3: Breakdown of Primary Research Respondents, by Company Type
Fig 4: Embryonal Rms
Fig 5: Rms Drug Candidates In Development (2018)
Fig 6: Rms Pipelinesplit, by Molecule Type (2018)
Fig 7: Rms Pipeline-Split, by Route of Administration (2018)
Fig 8: Breakdown of Clinical Trials, by Region
Fig 9: Breakdown of Clinical Trials, by Trial Status
Fig 10: Key Player Benchmarking
Fig 11: SWOT Analysis
Note: Product cover images may vary from those shown
3 of 2


Order Online - visit: https://www.researchandmarkets.com/reports/4517528